Prevalence of activated protein C resistance and analysis of clinical profile in thromboembolic patients. A Belgian prospective study

Journal of Internal Medicine

Volumn 241, Issue 5, 1997, Pages 427-433

  Hainaut, P ^a   Azerad, M A ^a   Lehmann, F ^a   Schlit, A F ^a   Zech, F ^a   Heusterspreute, M ^a   Philippe, M ^a   Col, C ^a   Lavenne, E ^a   Moriau, M ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

activated protein C resistance; APC R; coagulation; deep venous thrombosis; thromboembolism; thrombophilia

Indexed keywords

ACTIVATED PROTEIN C;

ADULT; ARTICLE; BELGIUM; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; GENE MUTATION; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 8244252287     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1997.139145000.x     Document Type: Article

References (32)

1. Schafer AI. Low-molecular-weight heparin: an opportunity for home treatment of venous thrombosis. N Engl J Med 1996; 334: 724-5.
2. Hirsh J, Prins MH, Samama M. Hemostasis and thrombosis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Basic Principles and Clinical Practice. Philadelphia: JB Lippincott, 1994; 1543-61.
3. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci 1993; 90: 1004-8.
4. Voorberg J, Roelse J, Koopman R, Buller H, Berends F, ten-Cate JW et al. Association of idiopathic venous thromboembolism with single point mutation at Arg 506 of factor V. Lancet 1994; 343: 1535-6.
5. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de-Ronde H et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
6. Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci 1994; 91: 1396-1400.
7. Zoller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis, Lancet 1994; 343: 1536-8.
8. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
9. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
10. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
11. Halbmayer WM, Haushofer A, Schön R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis 1994; 5: 51-7.
12. Cadroy Y, Sie P, Boneu P. Frequency of a defective response to activated protein C in patients with a history of venous thrombosis. Blood 1994; 83: 2008-9.
13. Zöller B, Nordlund L, Leksell H, Nilsson JE, von Schenk H. Rosén U, Jeppson JO et al. High prevalence of the FVR506Q mutation causing APC resistance in a region of southern Sweden with a high incidence of venous thrombosis. Thromb Res 1996; 83: 475-7.
14. Cumming AM, Fildes S, Pylypczuk CC, El-Metaal M, Burn AM, Wensley RT, Tait RC. Low incidence of resistance to activated protein C in patients with venous thrombosis. Br J Haematol 1994; 86 (Suppl. 1): 34.
15. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-93.
16. Cadroy Y, Sié P, Alhenc-Celas M, Aiach M. Evaluation of APC resistance in the plasma of patients with Q506 mutation of factor V (factor V Leiden) and treated by oral anticoagulants. Thromb Haemost 1995; 73: 734-5.
17. Legnani C, Palareti G, Biagi R, Coccheri S. Activated protein C resistance in deep-vein thrombosis. Lancet 1994; 343: 541-2.
18. Lindblad B, Svensson P, Dahlbäck B. Arterial and venous thromboembolism with fatal outcome and resistance to activated Protein C. Lancet 1994; 343: 917.
19. Samani NJ, Lodwick D, Martin D, Kimber P. Resistance to activated protein C and risk of premature myocardial infarction. Lancet 1994; 344: 1709-10.
20. Ridker P, Hennekens C, Lindpainter K, Stampfer M, Eisenberg P, Miletich J. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
21. Kontula K, Ylikorkala A, Miettinen H, Vuorio A, Kauppinen-Makelin R, Hamalainen L et al. Arg506Gln Factor V Mutation (Factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995; 73: 558-60.
22. Bertina RM, Protein S antigen. In: Jespersen J., Bertina RM, Haverkate F, eds. Ecat Assay Procedures. Lancaster: Kluwer Academic Publishers, 1992; 99-108.
23. Henkens CM, Bom VJ, Seinen AJ, van der Meer J, Sensitivity to activated protein C: influence of oral contraceptives and sex. Thromb Haemost 1995; 73: 402-4.
24. Trossaert M, Conard J, Horellou MH, Samama MM, Ireland H, Bayston TA, Lane DA. Modified APC resistance assay for patients on oral anticoagulants. Lancet 1994; 344: 1709.
25. Tosetto A, Rodeghiero F. Diagnosis of APC resistance in patients on oral anticoagulant therapy. Thromb Haemost 1995; 73: 732-3.
26. Le DT, Griffin JH, Greengard JS, Mujumdar V, Rapaport SI. Use of a generally applicable tissue factor-dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant. Blood 1995; 85: 1704-11.
27. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oralcontraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
28. Dahlbäck B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995; 85: 607-14.
29. Trossaërt M, Conard J, Horellou MH, Samaha M, Elalamy I., Samama MM. Résistance à la protéine C activée dans les accidents thrombo-emboliques veineux. Fréquence et manifestations cliniques. Presse Med 1995; 24: 209-12.
30. Samaha M, Trossart M, Conard J, Horellou MH, Elalamy I, Samama MM. Prevalence and patient profile in activated protein C resistance. Am J Clin Pathol 1995; 104: 450-4.
31. Ma DDF, Aboud MR, Williams GB, Isbister JP. Activated protein C resistance (APC) and inherited factor V (FV) missense mutation in patients with venous and arterial thrombosis in a haematology clinic. Aust NZ J Med 1995; 25: 151-4.
32. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-4.